Understanding FDA Accelerated Approval for Cancer Drugs

The FDA's accelerated approval pathway allows some cancer drugs to reach patients earlier, based on promising early results on a measure likely to predict clinical benefit, with a requirement to confirm that benefit in further studies after approval.

Standard full FDA approval typically requires large Phase III trial data demonstrating a clear clinical benefit, such as improved overall survival. Accelerated approval instead allows a drug to be approved based on an earlier, 'surrogate' endpoint — such as tumor response rate — that is reasonably likely to predict eventual clinical benefit, when there's an unmet medical need.

This pathway has allowed several lung cancer drugs, including some targeted therapies and immunotherapies, to reach patients years before a traditional full-approval timeline based on mature survival data would have allowed.

Drugs approved under this pathway are generally required to complete confirmatory trials afterward to verify the anticipated clinical benefit; if confirmatory data doesn't support the initial finding, the FDA can withdraw the accelerated approval, as has occurred with some drugs across various cancer types.